Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy.
Axillary lymph node dissection
Luminal subtypes
Neoadjuvant chemotherapy
Prediction
Sentinel lymph node biopsy
Stages
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
19
12
2023
accepted:
09
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
epublish
Résumé
Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for assessing axillary lymph node status in clinically node-negative breast cancer patients. However, the approach to axillary surgery after neoadjuvant treatment is still controversial. In the present study, our objective was to predict the pathological nodal stage based on SLNB results and the clinicopathological characteristics of patients who initially presented with clinical N1 positivity but whose disease status was converted to clinical N0 after neoadjuvant chemotherapy (NAC). After NAC, 150 clinically node-negative patients were included. The relationships between clinicopathologic parameters and the number of positive lymph nodes in SLNBs and ALNDs were assessed through binary/multivariate logistic regression analysis. Among 150 patients, 78 patients had negative SLNBs, and 72 patients had positive SLNBs. According to the ALND data of 21 patients with SLNB1+, there was no additional node involvement (80.8%), 1-2 lymph nodes were positive in 5 patients (19.2%), and no patient had ≥ 3 lymph nodes involved. Following the detection of SLNB1 + positivity, the rate of negative non-sentinel nodes were 75% in the luminal A/B subgroup, 100% in the HER-2-positive subgroup, and 100% in the triple-negative subgroup. Patients with a lower T stage (T1-3 vs. T4), fewer than 4 clinical nodes before NAC (< 4 vs. ≥4), and a decreased postoperative Ki-67 index (< 10% vs. stable/increase) were included. According to both univariate and multivariate analyses, being in the triple-negative or HER2-positive subgroup, compared to the luminal A/B subgroup (luminal A/B vs. HER2-positive/triple-negative), was found to be predictive of complete lymph node response. The number of SLNB-positive nodes, tumor-related parameters, and response to treatment may predict no additional nodes to be positive at ALND.
Sections du résumé
BACKGROUND
BACKGROUND
Sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) for assessing axillary lymph node status in clinically node-negative breast cancer patients. However, the approach to axillary surgery after neoadjuvant treatment is still controversial. In the present study, our objective was to predict the pathological nodal stage based on SLNB results and the clinicopathological characteristics of patients who initially presented with clinical N1 positivity but whose disease status was converted to clinical N0 after neoadjuvant chemotherapy (NAC).
MATERIALS AND METHODS
METHODS
After NAC, 150 clinically node-negative patients were included. The relationships between clinicopathologic parameters and the number of positive lymph nodes in SLNBs and ALNDs were assessed through binary/multivariate logistic regression analysis.
RESULTS
RESULTS
Among 150 patients, 78 patients had negative SLNBs, and 72 patients had positive SLNBs. According to the ALND data of 21 patients with SLNB1+, there was no additional node involvement (80.8%), 1-2 lymph nodes were positive in 5 patients (19.2%), and no patient had ≥ 3 lymph nodes involved. Following the detection of SLNB1 + positivity, the rate of negative non-sentinel nodes were 75% in the luminal A/B subgroup, 100% in the HER-2-positive subgroup, and 100% in the triple-negative subgroup. Patients with a lower T stage (T1-3 vs. T4), fewer than 4 clinical nodes before NAC (< 4 vs. ≥4), and a decreased postoperative Ki-67 index (< 10% vs. stable/increase) were included. According to both univariate and multivariate analyses, being in the triple-negative or HER2-positive subgroup, compared to the luminal A/B subgroup (luminal A/B vs. HER2-positive/triple-negative), was found to be predictive of complete lymph node response.
CONCLUSION
CONCLUSIONS
The number of SLNB-positive nodes, tumor-related parameters, and response to treatment may predict no additional nodes to be positive at ALND.
Identifiants
pubmed: 39030524
doi: 10.1186/s12893-024-02500-5
pii: 10.1186/s12893-024-02500-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213Informations de copyright
© 2024. The Author(s).
Références
Van der Ploeg IM, Nieweg OE, van Rijk MC, et al. Axillary recurrence after a tumor-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–84. [PubMed: 18406100].
doi: 10.1016/j.ejso.2008.01.034
pubmed: 18406100
Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs no Axillary dissection on 10-Year overall survival among women with invasive breast Cancer and Sentinel Node Metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–26. https://doi.org/10.1001/jama.2017.11470 .
doi: 10.1001/jama.2017.11470
pubmed: 28898379
pmcid: 5672806
Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the Axilla after a positive sentinel node in breast Cancer: 10-Year results of the Randomized Controlled EORTC 10981–22023 AMAROS trial. Clin Oncol. 2023;41(12):2159–65. https://doi.org/10.1200/JCO.22.01565 .
doi: 10.1200/JCO.22.01565
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf Version 4.2023.
Maggi N, Nussbaumer R, Holzer L, et al. Axillary surgery in node-positive breast cancer. Breast. 2022;62(Suppl 1):S50–3. https://doi.org/10.1016/j.breast.2021.08.018 .
doi: 10.1016/j.breast.2021.08.018
pubmed: 34511332
Yau C, Osdoit M, Noordaa MVD, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicenter pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–60. https://doi.org/10.1016/S1470-2045(21)00589-1 .
doi: 10.1016/S1470-2045(21)00589-1
pubmed: 34902335
Royce M, Mulkey F, Osgood C, et al. US Food and Drug Administration expanded adjuvant indication of Abemaciclib in High-Risk early breast Cancer. J Clin Oncol. 2023;41(18):3456–7. https://doi.org/10.1200/JCO.23.00615 .
doi: 10.1200/JCO.23.00615
pubmed: 37104738
Krop I, Ismaila N, Andre F, et al. Use of biomarkers to Guide decisions on Adjuvant systemic therapy for women with early-stage invasive breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline focused Update. J Clin Oncol. 2017;35(24):2838–47. https://doi.org/10.1200/JCO.2017.74.0472 .
doi: 10.1200/JCO.2017.74.0472
pubmed: 28692382
Vrabie EM, Alecu M, Cirimbei C et al. The Management of Axillary Lymph Nodes in Breast Cancer - A Retrospective Single-Centre Study. Chirurgia (Bucur). 2021 Mar-Apr;116(2):186–92. https://doi.org/10.21614/chirurgia.116.2.186 .
Lim SZ, Yoo TK, Lee SB, et al. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2024;203(1):95–102. https://doi.org/10.1007/s10549-023-07104-w .
doi: 10.1007/s10549-023-07104-w
pubmed: 37796365
Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast Cancer treated with Sentinel Node Biopsy alone after Neoadjuvant Chemotherapy-A Rare Event. JAMA Oncol. 2021;7(12):1851–5. https://doi.org/10.1001/jamaoncol.2021.4394 .
doi: 10.1001/jamaoncol.2021.4394
pubmed: 34617979
Montagna G, Mrdutt MM, Sun SX et al. Omission of Axillary Dissection following nodal downstaging with Neoadjuvant Chemotherapy. JAMA Oncol 2024 Apr 25:e240578. https://doi.org/10.1001/jamaoncol.2024.0578 . Epub ahead of print.
Peery GB, Pak J, Burkbauer L, et al. Omission of Axillary Dissection in Node positive breast Cancer after Neoadjuvant systemic therapy. J Surg Res. 2023;292:247–57. https://doi.org/10.1016/j.jss.2023.08.004 .
doi: 10.1016/j.jss.2023.08.004
pubmed: 37660548
Kantor O, Wakeman M, Weiss A, et al. Axillary Management after Neoadjuvant endocrine therapy for hormone receptor-positive breast Cancer. Ann Surg Oncol. 2021;28(3):1358–67. https://doi.org/10.1245/s10434-020-09073-6 .
doi: 10.1245/s10434-020-09073-6
pubmed: 32869154
Bi Z, Liu J, Chen P, et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer. 2019;26(3):373–7. https://doi.org/10.1007/s12282-018-00934-3 .
doi: 10.1007/s12282-018-00934-3
pubmed: 30666563
Wong SM, Basik M, Florianova L et al. Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer [Internet] Ann Surg Oncol 2020. https://doi.org/10.1245/s10434-020-09211-0 .
Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up [Internet]. Eur J Surg Oncol. 2020. https://doi.org/10.1016/j.ejso.2020.10.014 .
doi: 10.1016/j.ejso.2020.10.014
pubmed: 33092968
Almahariq MF, Levitin R, Quinn TJ, et al. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in breast Cancer patients with residual N1 nodal Disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28(2):930–40. https://doi.org/10.1245/s10434-020-08928-2 .
doi: 10.1245/s10434-020-08928-2
pubmed: 32712895
Sargent RE, Siegel E, Ito F, et al. Axillary lymph node recurrence following wire-directed sentinel lymph node dissection for breast cancer patients with biopsy-proven axillary metastases prior to neoadjuvant chemotherapy at a safety net medical center. J Surg Oncol. 2023;128(1):9–15. https://doi.org/10.1002/jso.27241 .
doi: 10.1002/jso.27241
pubmed: 36933187
Livi L, Meattini I. Radiotherapy or surgery for the axilla in node-positive breast cancer? Lancet Oncol. 2015;16(2):e53. https://doi.org/10.1016/S1470-2045(14)71134-9 .
doi: 10.1016/S1470-2045(14)71134-9
pubmed: 25638679
Nitz U, Gluz O, Kreipe KK, et al. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol. 2020;12:q58835920973130. https://doi.org/10.1177/1758835920973130 .
doi: 10.1177/1758835920973130
Boughey JC, Suman VJ, Mittendorf EA, et al. Alliance for clinical trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61. https://doi.org/10.1001/jama.2013.278932 .
doi: 10.1001/jama.2013.278932
pubmed: 24101169
pmcid: 4075763
Boughey JC, Ballman KV, Hunt KK, et al. Axillary Ultrasound after Neoadjuvant Chemotherapy and its impact on Sentinel Lymph Node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386–93. https://doi.org/10.1200/JCO.2014.57.8401 .
doi: 10.1200/JCO.2014.57.8401
pubmed: 25646192
pmcid: 4606058
Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19(1):667. https://doi.org/10.1186/s13063-018-3021-9 .
doi: 10.1186/s13063-018-3021-9
pubmed: 30514362
pmcid: 6278139
Weber WP, Matrai Z, Hayoz S, et al. Tailored axillary surgery in patients with clinically node-positive breast cancer: preplanned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57 – 18, ABCSG-53, GBG 101. Breast. 2021;60:98–110. https://doi.org/10.1016/j.breast.2021.09.004 .
doi: 10.1016/j.breast.2021.09.004
pubmed: 34555676
pmcid: 8463904
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10. https://doi.org/10.1016/S1470-2045(14)70460-7 .
doi: 10.1016/S1470-2045(14)70460-7
pubmed: 25439688
pmcid: 4291166
Meattini I, Salvestrini V, Becherini C. Radiation therapy on the axilla after neoadjuvant chemotherapy. Curr Opin Oncol. 2022;34(6):647–52. https://doi.org/10.1097/CCO.0000000000000882 .
doi: 10.1097/CCO.0000000000000882
pubmed: 35838229
Fan YJ, Li JC, Zhu DM, et al. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis. BMC Surg. 2023;23(1):209. https://doi.org/10.1186/s12893-023-02101-8 .
doi: 10.1186/s12893-023-02101-8
pubmed: 37495945
pmcid: 10369839